TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19535716
Drug: Control (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (IV acetaminophen combined with nalbuphine)
Study: 15009362
Drug: Periprostatic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periprostatic saline injection
Study: 9517769
Drug: Intravenous methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous methotrexate (MTX) 0.3 mg/kg once weekly plus daily oral low dose prednisone
Study: 9517769
Drug: Concomitant prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant prednisone dose of 7.5 mg/day
Study: 9517769
Drug: Weekly low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly low dose MTX in combination with low dose corticosteroids
Study: 23672928
Drug: Temsirolimus 25mg
Normalized name: TEMSIROLIMUS 25MG/ML INJ,SOLN
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus 25mg i.v. administered weekly in 4 week cycles
Study: 12526313
Drug: GM-CSF and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF and alpha-INF joint treatment (experimental group)
Study: 9395275
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine oestrogens (CEE) 0.625 mg
Study: 9395275
Drug: Oestradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oestradiol valerate 1 mg
Study: 9395275
Drug: Oestradiol implants
Normalized name: Oestradiol Implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestradiol implants 50 mg
Study: 9395275
Drug: Oestradiol +
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oestradiol + medroxyprogesterone acetate (MPA) 2 mg + 5 mg
Study: 9395275
Drug: Oestradiol +
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oestradiol + norethisterone acetate (NE) 2 mg + 1 mg
Study: 8195446
Drug: Electronic pressure‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic pressure‐controlled probing set at 25 g
Study: 20826244
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in addition to aspirin
Study: 28030444
Drug: Neostigmine (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (0.05 mg/kg)
Study: 23877110
Drug: Ultrasound-guided periradicular
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided periradicular injections
Study: 23877110
Drug: Computed tomography-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computed tomography-controlled periradicular injections
Study: 19491335
Drug: MK-0657 7
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0657 7 mg
Study: 19491335
Drug: Carbidopa/levodopa 25/250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbidopa/levodopa 25/250 mg (LD)
Study: 10758447
Drug: Granisetron 40
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron 40 microg kg-1 plus dexamethasone 8 mg
Study: 9438777
Drug: Irbesartan (AT1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (AT1 angiotensin II receptor antagonist)
Study: 3468891
Drug: Low-tar cigarettes
Normalized name: Coal Tar
DrugBank: Coal tar (DB11082)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-tar cigarettes (5 mg/cig.)
Study: 3468891
Drug: Medium-tar cigarettes
Normalized name: Coal Tar
DrugBank: Coal tar (DB11082)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-tar cigarettes (15 mg/cig.)
Study: 31237947
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 400 mg/d for 24 weeks
Study: 29391360
Drug: Gabapentin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (up to 2700 mg)
Study: 26897383
Drug: Fixed-dose glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fixed-dose glucagon stimulation test (FD-GST: 1 or 1.5 mg in patients >90 kg)
Study: 26897383
Drug: Weight-based glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weight-based glucagon stimulation test (WB-GST: 0.03 mg/kg)
Study: 26897383
Drug: Fixed-dose glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fixed-dose glucagon stimulation test (FD-GST)
Study: 20003095
Drug: Alverine citrate
Normalized name: alverine citrate
DrugBank: Alverine (DB01616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alverine citrate 60 mg with simeticone 300 mg three times daily for 4 weeks
Study: 12744893
Drug: Men C-CRM(197)
Normalized name: DIMETHICONE 30 mg in 1 mL TOPICAL CREAM [CHANCHI Vitamin C Cream]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Men C-CRM(197) conjugate vaccine
Study: 6362017
Drug: Quinine 10
Normalized name: quinine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine 10 mg base per kg body wt. 8 hourly for 7 days
Study: 6362017
Drug: Quinine 10
Normalized name: quinine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine 10 mg base per kg body wt. 8 hourly for the first 4 days then 15 mg base per kg body wt. 8 hourly for the next 3 days
Study: 6362017
Drug: Quinine 10
Normalized name: quinine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine 10 mg base per kg body wt. 8 hourly for 7 days and then sulfadoxine 30 mg per kg body wt. and pyrimethamine 1.5 mg per kg body wt.
Study: 28362563
Drug: Cadila MMR
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadila MMR vaccine
Study: 28362563
Drug: Serum MMR
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum MMR vaccine
Study: 22081489
Drug: Pomalidomide (0.5‐3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide (0.5‐3.5 mg/day) with or without prednisone
Study: 19176240
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy targeting blood glucose concentrations of 2.8-4.4 mmol/L in infants and 3.9-5.6 mmol/L in children throughout PICU stay (n=349)
Study: 19176240
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin therapy to prevent blood glucose from exceeding 11.9 mmol/L (n=351)
Study: 8734235
Drug: Corticosteroids (methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (methylprednisolone 1.5 mg.kg‐1 intravenously at the beginning of surgery and 1.5 mg.kg‐1 iv daily for three days after surgery)
Study: 1827006
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg isradipine twice daily
Study: 7053912
Drug: Propranolol combined
Normalized name: propranolol and other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol combined with lactate and glycerol infusions
Study: 29946756
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (20,000 IU of cholecalciferol weekly for 24 weeks)
Study: 24829053
Drug: Interscalene brachial
Normalized name: Brachiara mutica pollen
DrugBank: Urochloa mutica pollen (DB10716)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interscalene brachial plexus block (ISB) - 10 ml mepivacaine 1 % and 20 ml ropivacaine 0.375%
Study: 16730604
Drug: Self-Administered (SA)
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-Administered (SA)
Study: 16730604
Drug: Interviewer-Administered (IA)
Normalized name: magnesium aluminum silicate type Ia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interviewer-Administered (IA)
Study: 16730604
Drug: Paper-and-Pencil Self-Administered
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paper-and-Pencil Self-Administered (SA)
Study: 12738464
Drug: Infliximab 1
Normalized name: infliximab 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab 1 mg/kg
Study: 10874600
Drug: AAACa (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAACa (900 mg/day elemental calcium)
Study: 10874600
Drug: AACa (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: AACa (900 mg/day elemental calcium)
Study: 10874600
Drug: CaCO3 (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: CaCO3 (900 mg/day elemental calcium)
Study: 9059470
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (NO) at 40 ppm for 20 minutes
Study: 9059470
Drug: Air (control)
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air (control) inhaled for 20 minutes
Study: 22394471
Drug: Org 25935
Normalized name: ORG-25935
DrugBank: ORG-25935 (DB12220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 25935 (12 mg)
Study: 18706998
Drug: Intravenously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered budesonide
Study: 11039260
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate 2,500 mg/day (1,000 mg of calcium)
Study: 11039260
Drug: Calcium acetate
Normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium acetate 1,000 mg (254 mg of calcium)
Study: 6394349
Drug: Piretanide 6
Normalized name: piretanide 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide 6 mg b.d.
Study: 6394349
Drug: Piretanide 6
Normalized name: piretanide 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide 6 mg + Triamterene 50 mg b.d.
Study: 6394349
Drug: Triamterene 50
Normalized name: triamterene 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamterene 50 mg b.d.
Study: 23506257
Drug: Barrier cream
Normalized name: Ceramax Skin Barrier Cream
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Barrier cream (40% zinc oxide with cod liver oil formulation)
Study: 23776431
Drug: Low-vitamin B-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-vitamin B-6 diet (<0.5 mg/d)
Study: 18821708
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of glucosamine and chondroitin sulfate
Study: 15940172
Drug: Entero-sorption with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entero-sorption with pectin-containing medication
Study: 12463728
Drug: Low-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat meal (two slices of bread and 200 ml of apple juice)
Study: 12463728
Drug: High-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meal (two slices of bread with 30 gm of butter and 200 ml of apple juice)
Study: 10328649
Drug: Regenerative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regenerative therapy using bioactive glass
Study: 1754868
Drug: IS-5-MN 20
Normalized name: IS 5-MN
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IS-5-MN 20 mg b.i.d. or t.i.d.
Study: 1754868
Drug: s.r. nifedipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.r. nifedipine 20 mg b.i.d. or 40 mg b.i.d.
Study: 7127996
Drug: Flecainide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (200 to 300 mg b.i.d.)
Study: 31551206
Drug: Regorafenib 160
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 160 mg orally once daily for the first 21 days of each 28‐day cycle plus Best Supportive Care (BSC)
Study: 31551206
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m2 intravenously on Day 1 of each 21‐day cycle plus cisplatin 75 mg/m2 i.v. beginning 30 minutes after pemetrexed administration plus Best Supportive Care (BSC)
Study: 29149904
Drug: 7-day standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day standard triple therapy (lansoprazole, amoxicillin, and clarithromycin)
Study: 29149904
Drug: 10-day sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day sequential therapy (lansoprazole and amoxicillin for the first 5 days, followed by lansoprazole, clarithromycin, and metronidazole for another 5 days)
Study: 29149904
Drug: 10-day concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day concomitant therapy (lansoprazole, amoxicillin, clarithromycin, and metronidazole)
Study: 26335108
Drug: Interactive videogame
Normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive videogame therapy (VGT)
Study: 26335108
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy ROM activities (ST)
Study: 22947344
Drug: Subcutaneous allergen-specific
Normalized name: Pacific halibut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract
Study: 19237874
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (insulin titrated to maintain blood glucose levels within the range of 4.44‐6.11 mM)
Study: 17389707
Drug: Hormone-sensitive lipase
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone-sensitive lipase gene expression
Study: 3816921
Drug: Slow-release diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release diltiazem (120 mg)
Study: 3816921
Drug: Conventional diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional diltiazem tablet (120 mg)
Study: 30488789
Drug: Rivaroxaban (direct
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (direct oral anticoagulant)
Study: 24397361
Drug: Vaginal micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal micronized progesterone capsules 200 mg once daily from the day after insemination until next menstruation or continuing for up to 8 weeks of pregnancy.
Study: 1771216
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg dexamethasone phosphate
Study: 1771216
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg dexamethasone phosphate
Study: 21092353
Drug: Culturally adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally adapted CBT combined with antidepressants
Study: 21092353
Drug: Antidepressants alone
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants alone (treatment as usual)
Study: 7988854
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (3.6 mg goserelin depot injection on cycle day 22 followed by individualized HMG stimulation 14 days later)
Study: 2659475
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with slow-release theophylline (2 x 350 mg) and salbutamol aerosol
Study: 2659475
Drug: Salbutamol monotherapy
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol monotherapy (placebo capsules)
Study: 2659475
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with slow-release theophylline and salbutamol aerosol
Study: 1148964
Drug: Cephaloridine (prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephaloridine (prophylactic antibacterial therapy)
Study: 28524025
Drug: Esmolol (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (0.05 mg×kg‐1×h‐1, titrated to decrease heart rate by 20% or below 95 bpm)
Study: 28524025
Drug: Control (isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (isotonic saline at 3 mL/h for 24 hours)
Study: 21948965
Drug: Rifaximin 400
Normalized name: Rifaximin 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 400 mg three times daily for 20 days
Study: 19838080
Drug: Tdap and
Normalized name: metformin and ertugliflozin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap and TIV co-administered
Study: 19838080
Drug: Tdap and
Normalized name: metformin and ertugliflozin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap and TIV sequential administration (TIV followed by Tdap)
Study: 16759390
Drug: Lutein supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein supplementation (10 mg/d for 12 weeks followed by 30 mg/d for 12 weeks)
Study: 15568661
Drug: Single-dose morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose morning omeprazole
Study: 15568661
Drug: Single-dose morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose morning rabeprazole
Study: 15568661
Drug: Single-dose morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose morning famotidine
Study: 15568661
Drug: Single-dose evening
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-dose evening omeprazole
Study: 15568661
Drug: Single-dose evening
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-dose evening rabeprazole
Study: 9489411
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of chronic pulmonary tuberculosis with 4-6 antituberculous drugs for not less than one year after sputum culture conversion.
Study: 9489411
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy with 3 or 4 drugs for recently diagnosed pulmonary tuberculosis.
Study: 8454118
Drug: Discussion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discussion of treatment effects
Study: 29183926
Drug: Enhanced management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced management with 3 monthly follow-up
Study: 29183926
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual by the general practitioner
Study: 25752882
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg DEX
Study: 25752882
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg DEX
Study: 25752882
Drug: Prophylactic DEX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic DEX (4 mg) vs. steroid naïve cohort
Study: 17004982
Drug: Intravenous ferrous
Normalized name: Ferrous Fumarate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferrous sucrose 200 mg (two doses on days 2 and 4)
Study: 17004982
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous sulphate 200 mg twice daily for 6 weeks
Study: 17004982
Drug: Intravenous ferrous
Normalized name: Ferrous Fumarate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferrous sucrose
Study: 14762881
Drug: Irradiation (60-66
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irradiation (60-66 Gy over 30-33 daily fractions)
Study: 9205634
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1000 mg effervescent calcium tablet, Sandocal 1000)
Study: 7960357
Drug: 1% 8-MOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% 8-MOP bathing suit treatment
Study: 7960357
Drug: Placebo bathing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo bathing suit treatment
Study: 29437941
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (40 mg.kg(‐1))
Study: 27686002
Drug: Low-dose azathioprine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose azathioprine in combination with allopurinol
Study: 25070123
Drug: Thermal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal therapy using an infrared thermal blanket at 50°C for 40 minutes in addition to drug treatment
Study: 18485668
Drug: Grape antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape antioxidant dietary fiber (7.5 g/d)
Study: 18485668
Drug: Grape antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape antioxidant dietary fiber (7.5 g/d) in hypercholesterolemic subjects
Study: 11476456
Drug: Fexofenadine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine 15 mg twice daily
Study: 11476456
Drug: Fexofenadine 30
Normalized name: fexofenadine 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine 30 mg twice daily
Study: 9595871
Drug: Melatonin 5
Normalized name: melatonin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 5 mg taken 5 hours before the endogenous nocturnal plasma melatonin concentration reached 10 pg/mL
Study: 7802194
Drug: Hyaluronidase 50
Normalized name: Hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hyaluronidase 50 u.ml‐1 added to local anaesthetic mixture
Study: 15235828
Drug: Intravenous famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous famotidine (20 mg administered one hour before surgery)
Study: 15235828
Drug: Intramuscular famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular famotidine (20 mg administered one hour before surgery)
Study: 15235828
Drug: Oral famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral famotidine (20 mg administered the night before and on the morning of surgery)
Study: 21332976
Drug: AMC/DCBA Warm
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMC/DCBA Warm lozenge
Study: 21332976
Drug: AMC/DCBA Cool
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMC/DCBA Cool lozenge
Study: 21332976
Drug: Unflavoured, non‐medicated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unflavoured, non‐medicated lozenge